

Improved survival in myeloma patients—a nationwide registry study of 4,647 patients ≥ 75 years treated in Denmark and Sweden

Kari Lenita Falck Moore^{1,2,3} Ingemar Turesson,⁴ Anna Genell,⁵ Tobias W. Klausen,⁶ Dorota Knut-Bojanowska,⁷ Louise Redder,⁸ Ingigerdur Sverrisdottir,^{9,10} Jonathan Thorsen,¹¹ Annette J. Vangsted^{12#} and Cecilie H. Blimark^{9,13#} on behalf of the Nordic Myeloma Study Group

¹KG Jebsen Center for B-Cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway; ²Oslo Myeloma Center, Department of hematology, Oslo University Hospital, Oslo Norway; ³Department of Hematology and Oncology, Stavanger University Hospital, Stavanger, Norway; ⁴Department of Hematology, Skåne University Hospital Malmö/Lund, Malmö, Sweden; ⁵Regional Cancer Center of the Western Region, Sahlgrenska University Hospital, Gothenburg, Sweden; ⁶Department of Hematology, Herlev Hospital, Herlev, Denmark; ⁷Department of Hematology, Uddevalla Hospital, Uddevalla, Sweden; ⁸Department of Hematology, Odense University Hospital, Odense, Denmark; ⁹Department of Hematology, Sahlgrenska University Hospital, Gothenburg, Sweden; ¹⁰Faculty of Medicine, University of Iceland, Reykjavik, Iceland; ¹¹Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Denmark; ¹²Department of Hematology, Rigshospitalet, Copenhagen, Denmark and ¹³Institution of Internal Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

#AJV and CHB contributed equally as co-senior authors.

Correspondence: K.L.F. Moore.
k.l.f.moore@medisin.uio.no

Received: January 10, 2022.

Accepted: August 16, 2022.

Prepublished: October 27, 2022.

<https://doi.org/10.3324/haematol.2021.280424>

©2023 Ferrata Storti Foundation

Published under a CC BY-NC license



Supplementary data

Supplementary Table S1: Prevalence of plasma cell diseases in Denmark and Sweden (data from NORDCAN)				
	Denmark		Sweden	
Years	Females	Males	Females	Males
1963	3.5	3.8		
1964	4.1	4.0		
1965	4.6	4.7		
1966	5.0	5.4		
1967	5.1	5.7		
1968	5.2	6.0		
1969	5.6	6.4		
1970	5.4	5.8		
1971	5.2	6.3		
1972	5.0	5.8		
1973	5.5	5.9		
1974	5.6	5.9		
1975	6.6	6.3		
1976	6.9	7.3		
1977	8.0	7.7		
1978	7.9	8.6		
1979	8.6	9.1		
1980	8.9	8.6	16.8	17.8
1981	9.0	9.8	17.1	19.6
1982	9.4	10.5	17.3	20.1
1983	10.1	10.3	18.8	20.9
1984	10.4	10.8	20.2	21.5
1985	9.9	11.1	19.9	22.2
1986	9.5	11.1	19.7	23.1
1987	10.5	12.2	20.4	23.4
1988	11.1	12.2	20.3	22.9
1989	11.5	12.0	21.3	23.5
1990	11.4	12.0	21.1	23.6
1991	12.1	13.1	21.5	23.7
1992	13.3	13.5	20.8	24.1
1993	14.1	13.9	21.3	24.0
1994	14.0	14.5	21.5	24.4
1995	13.7	14.3	21.4	24.5
1996	14.0	15.3	21.4	24.8
1997	14.2	15.2	21.8	24.2
1998	14.7	15.0	22.3	24.9
1999	15.0	15.7	23.2	24.9
2000	16.0	16.0	23.3	26.0
2001	16.1	17.3	23.7	26.2
2002	16.0	18.4	23.8	26.4

2003	15.8	19.6	24.0	26.4
2004	17.4	20.4	24.5	27.1
2005	19.3	22.8	24.9	27.7
2006	20.7	23.5	25.4	28.6
2007	21.8	25.9	25.8	29.6
2008	22.9	28.4	26.9	31.6
2009	25.3	30.3	27.1	32.3
2010	26.2	32.0	28.1	34.1
2011	27.6	34.2	29.5	36.0
2012	29.1	36.0	29.8	37.3
2013	31.5	38.3	30.4	39.0
2014	34.6	40.2	31.3	40.7
2015	36.3	43.5	31.8	42.4
2016	38.3	46.9	33.0	43.8
2017	41.5	50.0	35.5	46.5
2018	44.2	53.2	36.6	48.3
Prevalence is measured in cases per 100 000				

Supplementary Table S2: Treatment regimes in Denmark and Sweden for patients ≥ 75 years				
Regime	Denmark		Sweden	
	All years N (%)	2017-18 N (%)	All years N (%)	2017-19 N (%)
VRd	65 (4.1)	25 (10.3)	56 (2.3)	53 (9.1)
VTd	27 (1.7)	2 (0.8)	42 (1.7)	29 (5.0)
VCd	56 (3.5)	21 (8.6)	144 (6.0)	31 (5.3)
MPV	222 (14.0)	75 (30.9)	427 (17.7)	173 (29.8)
MPR	19 (1.2)	0 (0.0)	22 (0.9)	1 (0.2)
MPT	185 (11.7)	2 (0.8)	421 (17.5)	22 (3.8)
Vd	169 (10.7)	39 (16.0)	368 (15.3)	138 (23.8)
Rd	79 (5.0)	29 (11.9)	92 (3.8)	73 (12.6)
MP	403 (25.5)	7 (2.9)	674 (28.0)	37 (6.4)
CTd	12 (0.8)	0 (0.0)	25 (1.0)	1 (0.2)
Cd	50 (3.2)	6 (2.5)	43 (1.8)	7 (1.2)
Td	62 (3.9)	2 (0.8)	34 (1.4)	9 (1.6)
Td-ixa	4 (0.3)	0 (0.0)	8 (0.3)	0 (0.0)
Steroid mono	69 (4.4)	6 (2.5)	38 (1.6)	2 (0.3)
Other	74 (4.7)	13 (5.3)	14 (0.6)	4 (0.7)
None	85 (5.4)	16 (6.6)		
Missing	107	42	52 (2.0)	28 (4.4)

N; number of patients. VRd; bortezomib, lenalidomide, dexamethasone. VTd; bortezomib, thalidomide, dexamethasone. VCd; bortezomib, cyclophosphamide, dexamethasone. MPV; melphalan, prednisolone, bortezomib. MPR; melphalan, prednisolone, lenalidomide. MPT; melphalan, prednisolone, thalidomide. Vd; bortezomib, dexamethasone. Rd; lenalidomide, dexamethasone. MP; melphalan, prednisolone. CTd; cyclophosphamide, thalidomide, dexamethasone. Cd; cyclophosphamide, dexamethasone. Td; thalidomide, dexamethasone. Td-ixa; thalidomide, dexamethasone, ixazomib. Mono; monotherapy.

Supplementary Table S3: Proportion of patients receiving IMiD and/or proteasome inhibitor as part of first line treatment by age group and country

Year of diagnosis	Sweden		Denmark	
	< 75 years N (%)	≥ 75 years N (%)	< 75 years N (%)	≥ 75 years N (%)
2005			19 (12.3)	15 (16.5)
2006			26 (13.9)	29 (29.3)
2007			54 (30.0)	27 (22.7)
2008	131 (43.7)	52 (29.9)	57 (29.4)	41 (41.8)
2009	222 (76.6)	75 (36.2)	138 (65.1)	46 (43.4)
2010	283 (90.7)	104 (49.1)	169 (84.5)	55 (56.1)
2011	326 (91.1)	113 (57.9)	193 (91.0)	52 (53.1)
2012	335 (94.6)	129 (58.6)	152 (80.9)	63 (55.8)
2013	327 (94.5)	144 (70.2)	180 (83.7)	71 (62.3)
2014	319 (91.4)	160 (73.1)	203 (93.1)	68 (67.3)
2015	355 (98.6)	177 (85.1)	194 (91.5)	97 (75.8)
2016	350 (97.5)	180 (85.3)	207 (94.1)	112 (80.0)
2017	381 (96.9)	211 (87.6)	229 (95.0)	107 (80.5)
2018	303 (98.1)	198 (93)	184 (94.8)	90 (81.8)
2019	219 (98.2)	147 (95.5)	34 (87.2)	31 (93.9)
Sum	3551 (89.8)	1690 (68.7)	2039 (71.1)	904 (57.2)

IMiD; immunomodulatory imide drugs. N; number of patients.

	Swedish patients < 75 years			Swedish patients ≥ 75 years			Danish patients < 75 years			Danish patients ≥ 75 years		
	≥VGPR N (%)	PR N (%)	NR N (%)	≥VGPR N (%)	PR N (%)	NR N (%)	≥ VGPR N (%)	PR N (%)	NR N (%)	≥VGPR N (%)	PR N (%)	NR N (%)
2005							37 (25.9)	67 (46.9)	39 (27.3)	9 (11.8)	23 (30.3)	44 (57.9)
2006							50 (28.2)	83 (46.9)	44 (24.9)	10 (11.9)	33 (39.3)	41 (48.8)
2007							63 (37.3)	58 (34.3)	48 (28.4)	18 (17.1)	35 (33.3)	52 (49.5)
2008	128 (44.3)	123 (42.6)	38 (13.1)	27 (19.7)	58 (42.3)	52 (38)	94 (51.9)	46 (25.4)	41 (22.7)	15 (17.4)	29 (33.7)	42 (48.8)
2009	137 (49.6)	107 (38.8)	32 (11.6)	41 (24.4)	77 (45.8)	50 (29.8)	109 (55.6)	42 (21.4)	45 (23.0)	11 (12.2)	38 (42.2)	41 (45.6)
2010	180 (60.6)	86 (29)	31 (10.4)	42 (26.8)	64 (40.8)	51 (32.5)	109 (56.5)	45 (23.3)	39 (20.2)	18 (20.0)	31 (34.4)	41 (45.6)
2011	197 (57.9)	98 (28.8)	45 (13.2)	37 (21.5)	72 (41.9)	63 (36.6)	128 (62.1)	46 (22.3)	32 (15.5)	16 (17.6)	29 (31.9)	46 (50.5)
2012	197 (58.8)	104 (31)	34 (10.1)	49 (26.2)	78 (41.7)	60 (32.1)	101 (55.2)	46 (25.1)	36 (19.7)	17 (17.0)	38 (38.0)	45 (45.0)
2013	207 (63.5)	83 (25.5)	36 (11)	46 (25.8)	78 (43.8)	54 (30.3)	115 (56.1)	50 (24.4)	40 (19.5)	25 (23.8)	43 (41.0)	37 (35.2)
2014	207 (61.8)	82 (24.5)	46 (13.7)	64 (34.2)	84 (44.9)	39 (20.9)	123 (58.6)	56 (26.7)	31 (14.8)	29 (32.6)	26 (29.2)	34 (38.2)
2015	206 (60.2)	102 (29.8)	34 (9.9)	58 (31.4)	78 (42.2)	49 (26.5)	129 (62.3)	53 (25.6)	25 (12.1)	38 (32.8)	40 (34.5)	38 (32.8)
2016	234 (68.8)	87 (25.6)	19 (5.6)	74 (39.4)	64 (34)	50 (26.6)	121 (57.6)	59 (28.1)	30 (14.3)	49 (38.6)	26 (20.5)	52 (40.9)
2017	255 (68.4)	79 (21.2)	39 (10.5)	80 (38.3)	81 (38.8)	48 (23)	142 (60.9)	61 (26.2)	30 (12.9)	44 (37.3)	36 (30.5)	38 (32.2)
2018	219 (77.7)	46 (16.3)	17 (6)	74 (40.4)	81 (44.3)	28 (15.3)	119 (64.0)	34 (18.3)	33 (17.7)	23 (24.2)	26 (27.4)	46 (48.4)
2019	149 (71)	42 (20)	19 (9)	62 (45.3)	52 (38)	23 (16.8)	19 (52.8)	6 (16.7)	11 (30.6)	12 (40.0)	8 (26.7)	10 (33.3)
Sum	2316 (61.8)	1039 (27.7)	390 (10.4)	654 (31.3)	867 (41.5)	567 (27.2)	1459 (53.3)	752 (27.5)	524 (19.2)	334 (23.8)	461 (32.9)	607 (43.3)

VGPR; very good partial response. PR; partial response. NR; no response. N; Number of patients.
Subgroup: Patients with 1-year follow-up report form who were treated and treatment data and response rate were reported.

Supplementary Table S5: Median observed and relative survival for myeloma patients by age group and country

Year	Swedish patients < 75 years				Swedish patients ≥ 75 years			
	Median OS (mos)	OS, 95% CI (mos)	Median RS (mos)	RS, 95% CI (mos)	Median OS (mos)	OS, 95% CI (mos)	Median RS (mos)	RS, 95% CI (mos)
2008-2009	64.6	54.1-71.3	68.3	61.4-77.4	20.3	17.9 - 24.2	24.5	20.6 - 29.6
2010-2011	63.7	59.5-70.2	69.0	62.4-84.4	21.5	18.8 - 23.9	24.6	22.4 - 29.8
2012-2013	73.4	65.9-80.2	80.2	72.8-89.8	22.1	18.6 - 27.2	29.2	23.6 - 33.4
2014-2015	73.8	68.0-81.6	81.0	73.9- NR	27.8	23.5 - 31.4	34.1	29.8 - 40.2
2016-2017	NR	NR-NR	NR	NR-NR	30.5	27.0 - 35.4	41.6	34.2 - 47.6
2018-2019	NR	NR-NR	NR	NR-NR	34.1	27.6 - 36.5	NR	34.9 - NR
Year	Danish patients < 75 years				Danish patients ≥ 75 years			
	Median OS (mos)	OS, 95% CI (mos)	Median RS (mos)	RS, 95% CI (mos)	Median OS (mos)	OS, 95% CI (mos)	Median RS (mos)	RS, 95% CI (mos)
2005-2007	49.7	45.8 - 56.5	54.1	47.8 - 63.2	19.7	14.9 - 23.2	24.6	19.8-33.8
2008-2010	53.9	49.0 - 60.4	58.9	52.8 - 66.8	20.9	17.4 - 25.2	26.0	21.7-32.3
2011-2012	65.9	59.2 - 75.2	74.8	64.7 - 87.8	19.8	13.0 - 26.5	23.8	18.6-39.8
2013-2014	72.8	61.4 - NR	85.1	71.8 - NR	23.9	17.9 - 32.3	34.0	23.9-43.2
2015-2016	NR	NR-NR	NR	NR-NR	29.0	24.0 - 33.6	36.1	31.2-48.9
2017-	NR	NR-NR	NR	NR-NR	29.8	24.9 - NR	NR	32.3- NR

CI; confidence interval. Mos; months. NR; not reached. OS; overall survival. RS; relative survival.

Supplementary Table S6: Observed and relative survival at 6 months, 1 year and 3 years by age group and country									
	Swedish patients < 75 years					Swedish patients ≥ 75 years			
Time period	Survival at (years)	Obs. survival (%)	95% CI (%)	Rel. survival (%)	95% CI (%)	Obs. survival (%)	95% CI (%)	Rel. survival (%)	95% CI (%)
2008-2009	0.5	94.7	92.9-96.5	95.1	93.4-96.9	75.7	71.7 - 79.9	78.2	74.1 - 82.5
2010-2011	0.5	93.0	91.1-94.9	93.5	91.7-95.4	76.7	72.9 - 80.7	79.0	75.1 - 83.1
2012-2013	0.5	94.5	92.9-96.2	95.0	93.3-96.6	77.9	74.2 - 81.7	80.5	76.7 - 84.4
2014-2015	0.5	93.3	91.6-95.1	93.8	92.0-95.6	77.6	74.0 - 81.3	80.1	76.5 - 84.0
2016-2017	0.5	95.0	93.5-96.5	95.5	94.0-97.0	81.6	78.4 - 85.0	83.9	80.6 - 87.4
2018-2019	0.5	94.8	93.3-96.4	95.2	93.7-96.8	80.7	77.5 - 84.0	83.2	80.0 - 86.6
2008-2009	1.0	88.6	86.1-91.1	89.4	86.9-92.0	65.3	61.0 - 70.0	69.4	64.8 - 74.4
2010-2011	1.0	88.2	85.8-90.5	89.1	86.8-91.5	62.9	58.6 - 67.5	66.7	62.2 - 71.6
2012-2013	1.0	89.1	86.8-91.4	89.9	87.6-92.3	65.5	61.4 - 70.0	69.9	65.5 - 74.7
2014-2015	1.0	89.2	87.0-91.4	90.1	87.9-92.4	68.1	64.2 - 72.3	72.2	68.0 - 76.6
2016-2017	1.0	91.8	89.9-93.7	92.7	90.8-94.6	73.8	70.2 - 77.7	77.9	74.0 - 81.9
2018-2019	1.0	91.8	89.8-93.8	92.7	90.7-94.7	72.1	68.5 - 75.8	76.4	72.6 - 80.3
2008-2009	3.0	67.0	63.4-70.8	69.2	65.4-73.1	30.9	26.8 - 35.6	37.0	32.1 - 42.6
2010-2011	3.0	69.4	66.1-72.9	71.7	68.3-75.2	32.4	28.4 - 37.1	38.9	34.0 - 44.4
2012-2013	3.0	71.7	68.5-75.1	74.0	70.7-77.5	34.5	30.4 - 39.0	42.1	37.2 - 47.7
2014-2015	3.0	73.2	70.1-76.4	75.6	72.4-78.9	41.1	37.0 - 45.6	48.6	43.8 - 54.0
2016-2017	3.0	79.0	76.2-81.9	81.6	78.7-84.5	45.2	41.1 - 49.6	53.6	48.8 - 58.8
2018-2019	3.0	79.4	76.0-82.9	82.1	78.6-85.7	44.3	39.0 - 50.2	52.5	46.3 - 59.5
	Danish patients < 75 years					Danish patients ≥ 75 years			
Time period	Survival at (years)	Obs. survival (%)	95% CI (%)	Rel. survival (%)	95% CI (%)	Obs. survival (%)	95% CI (%)	Rel. survival (%)	95% CI (%)
2005-2007	0.5	84.9	81.9 - 88.0	85.5	82.5 - 88.6	72.2	67.4 - 77.3	75.0	70.0 - 80.3
2008-2010	0.5	88.0	85.5 - 90.6	88.6	86.1 - 91.3	73.7	68.9 - 78.8	76.1	71.2 - 81.4
2011-2012	0.5	91.3	88.6 - 94.1	91.9	89.2 - 94.7	66.2	60.2 - 72.8	68.4	62.2 - 75.2
2013-2014	0.5	92.0	89.5 - 94.6	92.6	90.1 - 95.2	73.3	67.8 - 79.3	75.7	70.0 - 82.0
2015-2016	0.5	93.2	90.9 - 95.6	93.7	91.4 - 96.1	78.6	73.9 - 83.5	81.1	76.2 - 86.2
2017-	0.5	94.4	92.5 - 96.2	95.0	93.1 - 96.9	75.2	70.8 - 79.9	77.8	73.2 - 82.7
2005-2007	1.0	80.7	77.4 - 84.1	81.8	78.5 - 85.3	59.1	53.9 - 64.8	63.5	57.9 - 69.7
2008-2010	1.0	82.1	79.1 - 85.2	83.3	80.3 - 86.4	64.5	59.3 - 70.1	69.1	63.6 - 75.2
2011-2012	1.0	86.5	83.3 - 89.9	87.7	84.4 - 91.1	57.9	51.6 - 64.8	61.6	55.0 - 69.1
2013-2014	1.0	86.8	83.7 - 90.0	87.8	84.7 - 91.1	63.1	57.1 - 69.7	66.9	60.5 - 74.0
2015-2016	1.0	90.5	87.8 - 93.2	91.5	88.8 - 94.3	69.6	64.5 - 75.2	74.2	68.6 - 80.2
2017-	1.0	90.4	88.0 - 92.8	91.6	89.1 - 94.0	68.6	63.8 - 73.7	73.4	68.2 - 78.9
2005-2007	3.0	61.6	57.5 - 65.9	64.2	60.0 - 68.7	32.3	27.5 - 37.9	40.1	34.0 - 47.2
2008-2010	3.0	62.9	59.2 - 66.8	65.7	61.8 - 69.8	33.6	28.6 - 39.3	41.5	35.3 - 48.8
2011-2012	3.0	70.6	66.3 - 75.2	73.6	69.0 - 78.4	36.1	30.2 - 43.1	44.1	36.9 - 52.8
2013-2014	3.0	70.8	66.7 - 75.2	73.6	69.3 - 78.2	39.1	33.2 - 46.0	48.2	40.8 - 56.8
2015-2016	3.0	78.2	74.4 - 82.1	81.1	77.2 - 85.2	40.7	35.3 - 46.9	50.0	43.4 - 57.7
2017-	3.0	80.8	77.1 - 84.7	84.3	80.4 - 88.4	44.1	37.0 - 52.6	55.4	46.7 - 65.6

CI; confidence interval. Obs. survival; observed survival. Rel. survival; relative survival.

Supplementary Table S7: Observed and relative survival at 6 months, 1 year and 3 years by 3 age groups and country													
Swedish patients <75 years						Swedish patients 75-84 years				Swedish patients ≥ 85 years			
	Survival at (years)	OS (%)	95% CI (%)	RS (%)	95% CI (%)	OS (%)	95% CI (%)	RS (%)	95% CI (%)	OS (%)	95% CI (%)	RS (%)	95% CI (%)
008-2009	0.5	94.7	92.9-96.5	95.1	93.4-96.9	79.7	75.5 - 84.1	81.7	77.5 - 86.2	60.7	51.3 - 71.7	64.6	54.7 - 76.2
2010-2011	0.5	93.0	91.1-94.9	93.5	91.7-95.4	82.5	78.5 - 86.6	84.3	80.3 - 88.5	58.3	49.7 - 68.4	62.0	52.9 - 72.6
2012-2013	0.5	94.5	92.9-96.2	95.0	93.3-96.6	83.1	79.1 - 87.3	84.9	80.9 - 89.2	66.2	58.9 - 74.4	70.3	62.7 - 79.0
2014-2015	0.5	93.3	91.6-95.1	93.8	92.0-95.6	82.7	79.0 - 86.6	84.5	80.8 - 88.5	61.8	53.8 - 71.0	66.2	57.7 - 76.0
2016-2017	0.5	95.0	93.5-96.5	95.5	94.0-97.0	86.8	83.5 - 90.1	88.5	85.1 - 91.9	65.4	57.6 - 74.2	69.4	61.2 - 78.7
2018-2019	0.5	94.8	93.3-96.4	95.2	93.7-96.8	82.9	79.5 - 86.5	84.5	81.0 - 88.1	73.8	66.8 - 81.4	78.7	71.5 - 86.6
008-2009	1.0	88.6	86.1-91.1	89.4	86.9-92.0	71.6	67.0 - 76.6	75.1	70.3 - 80.3	41.6	32.5 - 53.2	47.0	36.8 - 59.9
2010-2011	1.0	88.2	85.8-90.5	89.1	86.8-91.5	69.0	64.3 - 74.1	72.1	67.2 - 77.4	43.5	35.1 - 53.9	49.2	39.8 - 60.9
2012-2013	1.0	89.1	86.8-91.4	89.9	87.6-92.3	72.3	67.6 - 77.3	75.6	70.7 - 80.8	50.3	42.8 - 59.2	57.0	48.5 - 66.9
2014-2015	1.0	89.2	87.0-91.4	90.1	87.9-92.4	74.7	70.5 - 79.3	77.8	73.4 - 82.5	48.0	39.9 - 57.7	53.8	44.9 - 64.5
2016-2017	1.0	91.8	89.9-93.7	92.7	90.8-94.6	80.0	76.2 - 84.0	83.1	79.2 - 87.3	54.3	46.3 - 63.7	60.8	51.9 - 71.2
2018-2019	1.0	91.8	89.8-93.8	92.7	90.7-94.7	77.2	73.4 - 81.2	80.1	76.1 - 84.2	56.0	48.4 - 64.9	63.9	55.3 - 73.8
008-2009	3.0	67.0	63.4-70.8	69.2	65.4-73.1	36.7	31.9 - 42.3	42.6	37.1 - 49.0	9.0	4.6 - 17.4	13.5	7.1 - 25.5
2010-2011	3.0	69.4	66.1-72.9	71.7	68.3-75.2	37.1	32.4 - 42.6	42.8	37.3 - 49.1	17.6	11.7 - 26.5	26.0	17.4 - 38.8
2012-2013	3.0	71.7	68.5-75.1	74.0	70.7-77.5	41.2	36.2 - 46.9	47.6	41.8 - 54.2	19.3	13.8 - 26.9	28.8	20.8 - 40.1
2014-2015	3.0	73.2	70.1-76.4	75.6	72.4-78.9	48.9	44.1 - 54.3	55.6	50.2 - 61.7	17.1	11.6 - 25.2	24.9	17.0 - 36.5
2016-2017	3.0	79.0	76.2-81.9	81.6	78.7-84.5	52.5	47.8 - 57.6	59.7	54.4 - 65.5	22.0	15.9 - 30.6	32.3	23.4 - 44.6
2018-2019	3.0	79.4	76.0-82.9	82.1	78.6-85.7	51.1	45.0 - 58.1	58.1	51.2 - 65.9	25.7	18.6 - 35.5	37.1	27.0 - 50.9
Danish patients <75 years						Danish patients 75-84 years				Danish patients ≥ 85 years			
	Survival at (years)	OS (%)	95% CI (%)	RS (%)	95% CI (%)	OS (%)	95% CI (%)	RS (%)	95% CI (%)	OS (%)	95% CI (%)	RS (%)	95% CI (%)
2008-2009	0.5	84.9	81.9 - 88.0	85.5	82.5 - 88.6	73.6	68.3 - 79.3	75.8	70.3 - 81.7	67.2	56.8 - 79.4	70.7	59.9 - 83.4
2010-2011	0.5	88.0	85.5 - 90.6	88.6	86.1 - 91.3	75.0	69.7 - 80.7	77.0	71.5 - 82.8	68.8	58.3 - 81.1	72.8	61.8 - 85.8
2012-2013	0.5	91.3	88.6 - 94.1	91.9	89.2 - 94.7	71.6	65.1 - 78.7	73.5	66.9 - 80.8	46.8	34.5 - 63.5	50.0	37.0 - 67.6
2014-2015	0.5	92.0	89.5 - 94.6	92.6	90.1 - 95.2	80.1	74.4 - 86.3	82.1	76.2 - 88.4	51.9	40.1 - 67.0	55.7	43.3 - 71.8
2016-2017	0.5	93.2	90.9 - 95.6	93.7	91.4 - 96.1	82.7	77.9 - 87.9	84.8	79.8 - 90.1	63.3	52.2 - 76.8	66.9	55.4 - 80.9
2018-2019	0.5	94.4	92.5 - 96.2	95.0	93.1 - 96.9	79.4	74.7 - 84.5	81.2	76.3 - 86.3	61.9	52.3 - 73.2	66.8	56.5 - 79.0
008-2009	1.0	80.7	77.4 - 84.1	81.8	78.5 - 85.3	63.4	57.7 - 69.7	67.2	61.1 - 73.9	43.3	32.9 - 56.9	49.8	37.9 - 65.5
2010-2011	1.0	82.1	79.1 - 85.2	83.3	80.3 - 86.4	67.1	61.4 - 73.3	70.9	64.9 - 77.5	54.7	43.8 - 68.4	62.2	49.9 - 77.5
2012-2013	1.0	86.5	83.3 - 89.9	87.7	84.4 - 91.1	63.9	57.1 - 71.6	67.4	60.2 - 75.5	36.2	24.7 - 52.9	39.6	27.2 - 57.6
2014-2015	1.0	86.8	83.7 - 90.0	87.8	84.7 - 91.1	71.3	64.9 - 78.5	74.7	68.0 - 82.2	37.0	26.2 - 52.4	42.2	30.0 - 59.4
2016-2017	1.0	90.5	87.8 - 93.2	91.5	88.8 - 94.3	73.6	68.0 - 79.7	77.4	71.5 - 83.8	55.0	43.7 - 69.1	61.2	48.8 - 76.9
2018-2019	1.0	90.4	88.0 - 92.8	91.6	89.1 - 94.0	74.4	69.3 - 80.0	78.0	72.6 - 83.8	50.3	40.6 - 62.5	59.1	47.8 - 73.0
008-2009	3.0	61.6	57.5 - 65.9	64.2	60.0 - 68.7	35.8	30.3 - 42.3	42.9	36.2 - 50.8	19.4	11.9 - 31.6	28.7	17.5 - 46.9
2010-2011	3.0	62.9	59.2 - 66.8	65.7	61.8 - 69.8	37.1	31.4 - 43.7	44.3	37.6 - 52.3	20.3	12.5 - 33.0	31.1	19.1 - 50.7
2012-2013	3.0	70.6	66.3 - 75.2	73.6	69.0 - 78.4	40.8	34.1 - 49.0	48.2	40.2 - 57.8	19.1	10.6 - 34.5	28.0	15.9 - 49.6
2014-2015	3.0	70.8	66.7 - 75.2	73.6	69.3 - 78.2	45.0	38.2 - 53.1	52.6	44.6 - 62.1	20.4	12.0 - 34.5	32.5	19.4 - 54.5

2016-2017	3.0	78.2	74.4 - 82.1	81.1	77.2 - 85.2	43.2	37.1 - 50.2	50.9	43.8 - 59.3	31.7	21.8 - 45.9	46.7	32.1 - 67.9
2018-2019	3.0	80.8	77.1 - 84.7	84.3	80.4 - 88.4	47.4	39.0 - 57.7	55.3	45.6 - 67.0	35.1	25.0 - 49.2	58.6	41.1 - 83.5